ATE521634T1 - Heterologes polypeptid der tnf familie - Google Patents

Heterologes polypeptid der tnf familie

Info

Publication number
ATE521634T1
ATE521634T1 AT01907139T AT01907139T ATE521634T1 AT E521634 T1 ATE521634 T1 AT E521634T1 AT 01907139 T AT01907139 T AT 01907139T AT 01907139 T AT01907139 T AT 01907139T AT E521634 T1 ATE521634 T1 AT E521634T1
Authority
AT
Austria
Prior art keywords
heterologue
polypeptide
tnf family
tnf
family
Prior art date
Application number
AT01907139T
Other languages
English (en)
Inventor
Paul Rennert
Jeffrey Thompson
Christine Ambrose
Teresa Cachero
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE521634T1 publication Critical patent/ATE521634T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01907139T 2000-02-11 2001-02-08 Heterologes polypeptid der tnf familie ATE521634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18167000P 2000-02-11 2000-02-11
PCT/US2001/004121 WO2001058949A2 (en) 2000-02-11 2001-02-08 Heterologous polypeptide of the tnf family

Publications (1)

Publication Number Publication Date
ATE521634T1 true ATE521634T1 (de) 2011-09-15

Family

ID=22665269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907139T ATE521634T1 (de) 2000-02-11 2001-02-08 Heterologes polypeptid der tnf familie

Country Status (8)

Country Link
US (2) US6875846B2 (de)
EP (1) EP1259544B1 (de)
JP (1) JP2003521931A (de)
AT (1) ATE521634T1 (de)
AU (2) AU3495301A (de)
CA (2) CA2399387C (de)
NZ (1) NZ520789A (de)
WO (1) WO2001058949A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
NZ513284A (en) * 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
MXPA02001665A (es) 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE329610T1 (de) * 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) 2000-06-16 2007-03-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
CN1636067A (zh) * 2001-08-03 2005-07-06 杰南技术公司 TACls和BR3多肽及其用途
AU2003221256A1 (en) * 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20050095243A1 (en) * 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
JP2007535307A (ja) * 2003-12-16 2007-12-06 ザイモジェネティクス，インコーポレイティド 腫瘍壊死因子Ｚｔｎｆ１２
EP1709072A1 (de) * 2004-01-29 2006-10-11 Genentech, Inc. Varianten der extrazellulären domäne von bcma und verwendungen dafür
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
EP1814577B1 (de) 2004-10-13 2014-04-23 The Washington University Verwendung von baff zur behandlung von sepsis
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
DE602006007323D1 (de) * 2005-01-28 2009-07-30 Biogen Idec Inc VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
WO2006083961A2 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EP2235059B1 (de) 2007-12-26 2015-02-18 Xencor, Inc. Fc-varianten mit modifizierter bindung an fcrn
US20110014190A1 (en) * 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20140178329A1 (en) * 2012-12-20 2014-06-26 Institucio Catalana De Recerca I Estudis Avancats (Icrea) Variants of the tnf superfamily and uses thereof
KR102135740B1 (ko) * 2014-02-27 2020-07-20 주식회사 원익아이피에스 기판 처리 장치 및 기판 처리 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5242599A (en) * 1992-02-07 1993-09-07 Betz Laboratories, Inc. Polymers for the treatment of boiler water
US5489519A (en) 1992-10-27 1996-02-06 Queen's University At Kingston Multidrug resistance protein
ES2210354T3 (es) 1996-03-14 2004-07-01 Human Genome Sciences, Inc. Factor de necrosis tumoral humano delta y epsilon.
WO1998018921A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
EE200000147A (et) 1997-09-12 2001-02-15 Biogen, Incorporated April - uus kasvuefekte omav valk
SK3532000A3 (en) 1997-09-12 2001-12-03 Apotech R & D Sa Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
JP2002516069A (ja) 1997-09-30 2002-06-04 ファルマシア・アンド・アップジョン・カンパニー Ｔｎｆ関連死リガンド
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
PT1818343E (pt) * 1998-01-23 2012-07-12 Hoffmann La Roche Anticorpos contra a il-12 humana
AU777536B2 (en) 1999-02-23 2004-10-21 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2018118080A1 (en) 2016-12-23 2018-06-28 Whirlpool Corporation Vacuum insulated panel for counteracting vacuum bow induced deformations

Also Published As

Publication number Publication date
US20030023038A1 (en) 2003-01-30
EP1259544B1 (de) 2011-08-24
US6875846B2 (en) 2005-04-05
EP1259544A2 (de) 2002-11-27
US20050124543A1 (en) 2005-06-09
CA2897626C (en) 2020-03-24
CA2399387A1 (en) 2001-08-16
JP2003521931A (ja) 2003-07-22
WO2001058949A3 (en) 2002-03-07
CA2399387C (en) 2015-11-03
AU2001234953B2 (en) 2006-03-16
CA2897626A1 (en) 2001-08-16
AU3495301A (en) 2001-08-20
WO2001058949A2 (en) 2001-08-16
NZ520789A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
ATE521634T1 (de) Heterologes polypeptid der tnf familie
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
DE60108617D1 (de) Leitende zementzusammensetzung
MXPA02012203A (es) Analogos de peptido 1 tipo glucagon.
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
MY126559A (en) Fungicidal 2-methoxybenzophenones
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
MY106964A (en) Fused polycyclic compounds, compositions, methods of manufacture, and their use as paf antagonists, antihistamines and/or antiinflammatory agents.
EA199900187A1 (ru) Лиганд, родственный фактору некроза опухоли
BG105028A (en) Bridged indenopyrrolocarbazoles
HRP20010117B1 (en) Novel salt form of pantoprazole
DK0585939T4 (da) TNF-ligander
ATE191224T1 (de) Tnf-inhibitoren
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE50003634D1 (de) SPRAY, ENTHALTEND UBICHINON Qn
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
IS5902A (is) Notkun á asýlkarnitínum sem miðlum gegn æxli
PL365687A1 (en) Novel trioxepan compounds
Shaw Genetic alterations to artificial soils by earthworms
IT8822682A0 (it) Conglomerato cementizio, particolarmente per mattonelle del tipo detto marmetta.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties